Compare Davita Inc (DVA) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.55 (market cap $77.43B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 6.9× Davita Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| DVA | MDLZ | |
|---|---|---|
Market Cap | $11.29B | $77.43B |
Volume | 582,204 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $64.99 |
52-Week Low | $103.87 | $51.51 |
Typical Hold Time | 113 Days | 107 Days |
Enterprise Value | $24.01B | $97.78B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Mondelez International (MDLZ) trades at $59.38, down 0.4% with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.73 beating expectations of $0.68. Revenue reached $38.54 billion in 2025, with an 8.86% net income margin and solid cash flow generation of $795 million. Analyst consensus remains strongly bullish with a $70.29 price target, representing 18% upside potential from current levels.
MDLZ presents a compelling investment case with consistent earnings outperformance, attractive dividend yield, and strong brand portfolio. However, investors face risks from cocoa cost volatility, competitive pressures, and margin compression. The stock's current valuation at 21.75 P/E offers reasonable entry point for long-term investors seeking defensive exposure in consumer staples with global growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
